Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Gains from Investment Securities (2016 - 2026)

Tenax Therapeutics' Gains from Investment Securities history spans 5 years, with the latest figure at $150000.0 for Q4 2017.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $150000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $150000.0, a N/A change, with the full-year FY2023 number at -$1000.0, down 134.47% from a year prior.
  • Gains from Investment Securities hit $150000.0 in Q4 2017 for Tenax Therapeutics, down from $3.8 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TENX hit a ceiling of $4.3 million in Q2 2017 and a floor of -$2519.0 in Q2 2014.
  • Historically, Gains from Investment Securities has averaged $1.1 million across 5 years, with a median of $50890.5 in 2013.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 122.22% in 2014 and later surged 9146.93% in 2015.
  • Tracing TENX's Gains from Investment Securities over 5 years: stood at $50678.0 in 2013, then dropped by 0.99% to $50175.0 in 2014, then plummeted by 90.46% to $4785.0 in 2015, then skyrocketed by 1153.92% to $60000.0 in 2016, then surged by 150.0% to $150000.0 in 2017.
  • Business Quant data shows Gains from Investment Securities for TENX at $150000.0 in Q4 2017, $3.8 million in Q3 2017, and $4.3 million in Q2 2017.